Sirolimus
- Generic Name
- Sirolimus
- Brand Names
- Fyarro, Hyftor, Rapamune
- Drug Type
- Small Molecule
- Chemical Formula
- C51H79NO13
- CAS Number
- 53123-88-9
- Unique Ingredient Identifier
- W36ZG6FT64
- Background
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria Streptomyces hygroscopicus, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive a...
- Indication
Sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. In patients at low-to moderate-immunologic risk, it is recommended that sirolimus be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn two to four months after transplantation. In pati...
- Associated Conditions
- Chordomas, Facial Angiofibroma, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Lymphangioleiomyomatosis (LAM), Renal Angiomyolipomas, Transplanted Organ Rejection, Metastatic malignant Perivascular Epithelioid Cell Neoplasms, Unresectable, locally advanced malignant Perivascular Epithelioid Cell Neoplasms
- Associated Therapies
- -
UB-VV400 in Combination with Rapamycin in Relapsed or Refractory B-cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT06743503
Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Not specified
- Target Recruit Count
- 84
- Registration Number
- NCT06722586
- Locations
- 🇨🇳
Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳Qilu Hospital of Shandong University, Jinan, Shangdong, China
🇨🇳West China Hospital, Sichuan University, Chengdu, Sichuan, China
Sirolomus Adjuvant Treatment of Focal Refractory Epilepsy (SATFRE)
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Xuanwu Hospital, Beijing
- Target Recruit Count
- 15
- Registration Number
- NCT06719791
RESTOR: PK/PD mTORi Inhibition in Older Adults
- Conditions
- Interventions
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2024-10-26
- Target Recruit Count
- 194
- Registration Number
- NCT06658093
- Locations
- 🇺🇸
The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
The Safety and Efficacy of Rapamycin on Communicating Hydrocephalus Secondary to Intraventricular Hemorrhage
- Conditions
- Interventions
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Beijing Tiantan Hospital
- Target Recruit Count
- 53
- Registration Number
- NCT06563817
- Locations
- 🇨🇳
Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China
The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- AgelessRx
- Target Recruit Count
- 67
- Registration Number
- NCT06550271
- Locations
- 🇺🇸
AgelessRx, Ann Arbor, Michigan, United States
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Umoja Biopharma
- Target Recruit Count
- 106
- Registration Number
- NCT06528301
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Washington University School of Medicine/Siteman Cancer Center, Saint Louis, Missouri, United States
The Safety and Efficiency of Sirolimus in Primary Antiphospholipid Syndrome: A Randomized Control Study
- Conditions
- Interventions
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT06504420
Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell AntibodY
- Conditions
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Children's National Research Institute
- Target Recruit Count
- 12
- Registration Number
- NCT06358638
- Locations
- 🇺🇸
Children's National Hospital, Washington, District of Columbia, United States
Safety Study for the Use of Rapamycin in Children With Familial Adenomatous Polyposis
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 25
- Registration Number
- NCT06308445
- Locations
- 🇫🇷
CHU Montpellier Hôpital Arnaud de Villeneuve, Montpellier, France
🇫🇷CHU Bordeaux Hôpital Pellegrin, Bordeaux, France
🇫🇷CHU Toulouse Hôpital des Enfants, Toulouse, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.